Results 231 to 240 of about 18,301 (299)
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen +7 more
wiley +1 more source
Association of SPISE with prevalent and incident MASLD: a two-stage population-based study and development of a risk prediction model. [PDF]
Cheng Y, Wang J.
europepmc +1 more source
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang +7 more
wiley +1 more source
Risk functions with outcome measurement error. [PDF]
Edwards JK +7 more
europepmc +1 more source
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang +13 more
wiley +1 more source
Prognostic Preoperative Factors in Surgical Patients with Colorectal Liver Metastases: A Nationwide Multicenter Study. [PDF]
Knøfler LA +9 more
europepmc +1 more source
Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia +7 more
wiley +1 more source
Structural and Non-Structural Deterioration After Biological Aortic Valve Replacement: Long-Term Outcomes of 918 High-Risk Patients. [PDF]
Hlavička J +8 more
europepmc +1 more source
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin +11 more
wiley +1 more source
A quantile cure model with partially functional covariate effects. [PDF]
Chen CM, Peng Y.
europepmc +1 more source

